阅读说明：本技术 用于结合il-17的肽配体 (Peptide ligands for binding IL-17 ) 是由 D·特夫 G·穆德 S·帕万 于 2019-06-18 设计创作，主要内容包括：一种IL-17特异性的肽配体,其包含多肽和分子支架,所述多肽包含三个选自半胱氨酸、L-2,3-二氨基丙酸(Dap)、N-β-烷基-L-2,3-二氨基丙酸(N-AlkDap)和N-β-卤代烷基-L-2,3-二氨基丙酸(N-HAlk Dap)的残基,条件是所述三个残基中的至少一个选自Dap、N-AlkDap或N-HAlkDap,所述三个残基被至少两个环序列隔开,肽通过多肽的Dap或N-AlkDap或N-HAlkDap残基经共价烷基氨基键以及通过多肽的半胱氨酸残基(当所述三个残基包括半胱氨酸时)经硫醚键与支架连接,从而在分子支架上形成两个多肽环。还提供了药物缀合物,其包含与一个或多个效应基团缀合的肽配体,以及提供了包含缀合物的药物组合物。(An IL-17 specific peptide ligand comprising a polypeptide and a molecular scaffold, the polypeptide comprising three residues selected from cysteine, L-2, 3-diaminopropionic acid (Dap), N- β -alkyl-L-2, 3-diaminopropionic acid (N-AlkDap), and N- β -haloalkyl-L-2, 3-diaminopropionic acid (N-HAlk Dap), with the proviso that at least one of the three residues is selected from Dap, N-AlkDap, or N-HAlk Dap, the three residues are separated by at least two loop sequences, and the peptide is linked to the scaffold via covalent alkyl amino bonds through the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and via thioether bonds through the cysteine residues of the polypeptide (when the three residues include cysteine) to form two polypeptide loops on the molecular scaffold. Also provided are drug conjugates comprising a peptide ligand conjugated to one or more effector groups, and pharmaceutical compositions comprising the conjugates.)

1. A peptide ligand specific for IL-17, comprising a polypeptide and a molecular scaffold, the polypeptide comprising three residues selected from cysteine, L-2, 3-diaminopropionic acid (Dap), N- β -alkyl-L-2, 3-diaminopropionic acid (N-AlkDap), and N- β -haloalkyl-L-2, 3-diaminopropionic acid (N-HAlkdap), with the proviso that at least one of the three residues is selected from Dap, N-AlkDap, or N-HAlkdap, the three residues being separated by at least two loop sequences, the peptide being linked to the scaffold via a covalent alkyl amino bond through the Dap or N-AlkDap or N-HAlkdap residue of the polypeptide and via a thioether bond through the cysteine residue of the polypeptide when the three residues comprise cysteine, thereby forming two polypeptide loops on the molecular scaffold.

2. The peptide ligand as defined in claim 1, wherein the peptide ligand comprises an amino acid sequence selected from the group consisting of:

C_i-X₁-C_ii-X₂-C_iii

wherein:

C_i、C_iiand C_iiiIndependently cysteine, L-2, 3-diaminopropionic acid (Dap), N-beta-alkyl-L-2, 3-diaminopropionic acid (N-AlkDap) or N-beta-haloalkyl-L-2, 3-diaminopropionic acid (N-HAlkdap), with the proviso that C is_i、C_iiAnd C_iiiIs Dap, N-AlkDap or N-HAlkDap; and is

X₁And X₂Represents an amino acid residue between cysteine, Dap, N-AlkDap or N-HAlkDap residues, wherein X₁And X₂Each independently having from 2 to 7 amino acid residues.

3. A peptide ligand as defined in any preceding claim, wherein C_i、C_iiAnd C_iiiTwo of (a) are selected from Dap, N-AlkDap or N-HAlkDap, and C_i、C_iiAnd C_iiiThe third of (A) is cysteine, preferably A_iiIs cysteine.

4. A peptide ligand as defined in claim 1 or 2, wherein C_i、C_iiAnd C_iiiOne of them is selected from Dap, N-AlkDap or N-HAlkDap, C_i、C_iiAnd C_iiiThe remainder of (a) is cysteine.

5. The peptide ligand as defined in any one of the preceding claims, wherein the molecular scaffold is 1,3, 5-tri (methylene) benzene (TBMB).

6. A peptide ligand as defined in any preceding claim, which is specific for IL-17A and comprises an amino acid sequence selected from SEQ ID NOs 1 to 3:

C_iPQDLELC_iiTFLFGDC_iii(SEQ ID NO：1)；

C_iDQDELMC_iiFLTGHQC_iii(SEQ ID NO: 2); and

C_iPENELYC_iiFLSSQQC_iii(SEQ ID NO：3)；

or a pharmaceutically acceptable salt thereof,

wherein C is_i、C_iiAnd C_iiiIndependently cysteine, L-2, 3-diaminopropionic acid (Dap), N-beta-alkyl-L-2, 3-diaminopropionic acid (N-AlkDap) or N-beta-haloalkyl-L-2, 3-diaminopropionic acid (N-HAlkdap), with the proviso that C is_i、C_iiAnd C_iiiIs Dap, N-AlkDap or N-HAlkDap.

7. A peptide ligand as defined in claim 6, which comprises an amino acid sequence selected from the group consisting of:

A-(SEQ ID NO：1)-A；

a- (SEQ ID NO: 2) -A; and

SEQ ID NO：3，

such as A- (SEQ ID NO: 1) -A.

8. A peptide ligand as defined in any one of claims 1 to 5, which is specific for IL-17E and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6 to 7 amino acid sequence:

C_iGYDYYC_iiALYDIC_iii(SEQ ID NO: 6); and

C_iLWKDNC_iiTHWSLC_iii(SEQ ID NO：7)；

or a pharmaceutically acceptable salt thereof,

wherein C is_i、C_iiAnd C_iiiIndependently cysteine, L-2, 3-diaminopropionic acid (Dap), N-beta-alkyl-L-2, 3-diaminopropionic acid (N-AlkDap) or N- β -haloalkyl-L-2, 3-diaminopropionic acid (N-HAlkdap), with the proviso that C_i、C_iiAnd C_iiiIs Dap, N-AlkDap or N-HAlkDap.

9. A peptide ligand as defined in claim 8, which comprises an amino acid sequence selected from the group consisting of:

a- (SEQ ID NO: 6) -A; and

A-(SEQ ID NO：7)-A，

such as A- (SEQ ID NO: 6) -A.

10. A peptide ligand as defined in any one of claims 1 to 5, which is specific for IL-17F and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4 to 5 amino acid sequence:

C_iDHSDFIC_iiWLNNFNC_iii(SEQ ID NO: 4); and

C_iGQC_iiSFSYWLNC_iii(SEQ ID NO：5)；

or a pharmaceutically acceptable salt thereof,

wherein C is_i、C_iiAnd C_iiiIndependently cysteine, L-2, 3-diaminopropionic acid (Dap), N-beta-alkyl-L-2, 3-diaminopropionic acid (N-AlkDap) or N-beta-haloalkyl-L-2, 3-diaminopropionic acid (N-HAlkdap), with the proviso that C is_i、C_iiAnd C_iiiIs Dap, N-AlkDap or N-HAlkDap.

11. A peptide ligand as defined in claim 10, which comprises an amino acid sequence selected from the group consisting of:

a- (SEQ ID NO: 4) -A; and

A-(SEQ ID NO：5)-A，

such as A- (SEQ ID NO: 5) -A.

12. The peptide ligand as defined in claim 5, wherein the peptide ligand comprises an amino acid sequence selected from one or more of the peptide ligand sequences listed in Table 2A 1-A6, or a pharmaceutically acceptable salt thereof, with the proviso that one or more cysteine residues in the peptide ligand sequences A1-A6 are substituted with Dap, N-AlkDap, or N-HAlkDap.

13. The peptide ligand as defined in any one of claims 1 to 12, wherein said IL-17 is human IL 17.

14. The peptide ligand as defined in any one of the preceding claims, wherein the peptide ligand is specific for IL-17A, IL-17E or IL-17F.

15. A drug conjugate comprising a peptide ligand as defined in any one of claims 1 to 14 conjugated with one or more effectors and/or functional groups.

16. A drug conjugate comprising a peptide ligand as defined in any one of claims 1 to 14 conjugated to one or more cytotoxic agents.

17. The drug conjugate as defined in claim 16, wherein the cytotoxic agent is selected from DM-1 and MMAE.

18. A pharmaceutical composition comprising a peptide ligand as claimed in any one of claims 1 to 14 or a drug conjugate as claimed in any one of claims 15 to 17 in combination with one or more pharmaceutically acceptable excipients.

19. A peptide ligand as defined in any one of claims 1 to 14 or a drug conjugate as defined in any one of claims 15 to 17 for use in the prevention, inhibition or treatment of a disease or condition mediated by IL-17.

Technical Field

The present invention relates to peptide ligands that are high affinity binders for IL-17. The invention also includes drug conjugates comprising the peptides conjugated to one or more effectors and/or functional groups, pharmaceutical compositions comprising the peptide ligands and drug conjugates, and uses of the peptide ligands and drug conjugates in preventing, inhibiting, or treating IL-17 mediated diseases or disorders.

In particular, the present invention relates to peptide ligands of this type having a novel chemical structure for forming two or more bonds between a peptide and a scaffold molecule.

Background

Different research groups have previously tethered peptides to scaffold moieties by the formation of two or more thioether bonds between cysteine residues of the peptides and appropriate functional groups of the scaffold molecules. For example, methods for producing drug candidate compounds by attaching cysteine-containing peptides to molecular scaffolds such as tris (bromomethyl) benzene are disclosed in WO 2004/077062 and WO 2006/078161.

The advantage of using cysteine thiols to create covalent thioether bonds to achieve cyclization is their selectivity and biorthogonal reactivity. Thiol-containing linear peptides can be cyclized with a thiol-reactive scaffold compound, such as 1,3,5 Tribromomethylbenzene (TBMB), to form a bicyclic peptide, the resulting product containing three thioethers at the benzyl position. The overall reaction of a linear peptide with TBMB to form a cyclic bicyclic peptide with a thioether bond is shown in figure 1.

There is a need for an alternative chemistry for coupling peptides to scaffold moieties to form cyclic peptide structures that employs suitable alternatives to thioether moieties to achieve compatibility with different peptides, changes in physicochemical properties (e.g., improved solubility), changes in biodistribution, and other advantages.

WO2011/018227 describes a method for altering the conformation of a first peptide ligand or a first set of peptide ligands (wherein each peptide ligand comprises at least two reactive groups covalently linked to a molecular scaffold separated by a loop sequence, the molecular scaffold forming a covalent bond with the reactive groups) to produce a second peptide ligand or a second set of peptide ligands, the method comprising assembling the second derivative or second set of derivatives from peptides and scaffolds of the first derivative or first set of derivatives, plus one of the following steps: (a) altering at least one reactive group; or (b) altering the properties of the molecular scaffold; or (c) altering the bond between at least one reactive group and the molecular scaffold; or any combination of (a), (b), or (c).

Our earlier pending applications PCT/EP2017/083953 and PCT/EP2017/083954, filed on 20.12.2017, describe bicyclic peptides in which one or more thioether bonds to the scaffold molecule have been substituted with alkyl amino bonds.

Interleukin 17(IL-17), also known as IL-17A and CTLA-8, is a pro-inflammatory cytokine that stimulates the secretion of a variety of other cytokines in a variety of cell types. For example, IL-17 induces IL-6, IL-8, G-CSF, TNF-a, IL-1 β, PGE2 and IFN- γ as well as a number of chemokines and other effectors (see Gaffen, SL (2004) Arthritis Research & Therapy 6, 240-.

IL-17 is expressed by TH17 cells, which TH17 cells are involved in inflammatory pathologies and autoimmunity. It is also expressed by CD8+ T cells, γ δ cells, NK cells, NKT cells, macrophages and dendritic cells. IL-17 and Thl7 are associated with the pathogenesis of a variety of autoimmune and inflammatory diseases, but are critical for host defense against many microorganisms (especially extracellular bacteria and fungi). Human IL-17A is a glycoprotein with an Mw of 17,000 daltons (Spriggs et al (1997) J Clin Immunol, 17, 366-. IL-17 can form homodimers or heterodimers with its family member IL-17F. IL-17 binds to IL-17RA and IL-17RC to mediate signaling. IL-17 signals through its receptor, activating NF-KB transcription factors as well as various MAPKs (see Gaffen, SL (2009) Nature Rev Immunol 9, 556-567).

IL-17 can act in concert with other inflammatory cytokines (e.g., TNF-. alpha., IFN-. gamma., and IL-I. beta.) to mediate proinflammatory effects (see Gaffen, SL (2004) Arthritis Research & Therapy 6, 240-. Elevated IL-17 levels are associated with a number of diseases including Rheumatoid Arthritis (RA), bone erosion, intraperitoneal abscesses, inflammatory bowel disease, allograft rejection, psoriasis, angiogenesis, atherosclerosis, asthma and multiple sclerosis (see Gaffen, SL (2004) supra and US 2008/0269467). Higher serum concentrations of IL-17 were found in Systemic Lupus Erythematosus (SLE) patients and it was recently established that it can act alone or in concert with B cell activating factor (BAFF) to control B cell survival, proliferation and differentiation into immunoglobulin producing cells (Doreau et al (2009) Nature Immunology 7, 778-7859). IL-17 is also associated with ocular surface diseases such as dry eye (WO 2010/062858 and WO 2011/163452). IL-17 has also been implicated in playing a role in ankylosing spondylitis (Appel et al (2011) Arthritis Research and Therapy, 13, R95) and psoriatic Arthritis (Mclnnes et al (2011) Arthritis & Rheumatism 63(10), 779).

IL-17 and IL-17-producing TH17 cells have also recently been implicated in certain cancers (Ji and Zhang (2010) Cancer Immunol Immunother 59, 979-987). For example, TH17 cells expressing IL-17 have been shown to be associated with multiple myeloma (Prabhala et al (2010) Blood, online DOI10.1182/Blood-2009-10-246660) and associated with poor prognosis in HCC patients (Zhang et al (2009) J Hepatology 50, 980-89). Furthermore, Breast Cancer-associated macrophages were found to express IL-17(Zhu et al (2008) Breast Cancer Research 10, R95). However, the role of IL-17 in cancer is in many cases unclear. In particular, IL-17 and IL-17 producing TH17 cells have been identified as having both positive and negative effects in tumor immunity, sometimes in the same Cancer type (Ji and Zhang (2010) Cancer Immunol Immunother 59, 979-.

IL-17A binds to the IL-17 receptor (RA/RC complex). IL-17A may exist as a homodimer or as a heterodimer with IL-17F. IL-17A expression is restricted (lymphocytes, neutrophils and eosinophils). IL-17A is associated with airway inflammation and psoriasis.

IL-17E (also known as IL-25) binds to the IL-17 receptor (RA/RB complex). IL-17E is associated with airway inflammation and recruits eosinophils to lung tissue. IL-17E is distantly associated (17%) with IL-17A. IL-17E expression is very low (Th2, eosinophils, mast cells and macrophages).

IL-17F binds to the IL-17 receptor (RA/RC complex) with a lower affinity than IL-17A. It has a similar expression pattern to IL-17A. IL-17F is associated with airway inflammation and psoriasis. IL-17F is most closely associated with IL-17A (44-55%), and may exist as a homodimer or as a heterodimer with IL-17A.

Our earlier pending application GB1720932.1 filed 12, 15, 2017 describes bicyclic peptide ligands with high binding affinity for IL-17. These applications further describe conjugates of the peptide ligands with therapeutic agents, particularly cytotoxic agents.

Disclosure of Invention

The inventors of the present invention have found that the substitution of thioether bonds in cyclic peptides having affinity for IL-17 by alkyl amino bonds results in cyclic peptide conjugates that exhibit IL-17 affinity similar to the corresponding conjugates prepared entirely using thioether bonds. It is expected that substitution of the thioether bond with an alkylamino linkage will result in improved solubility and/or improved oxidative stability of the conjugates according to the invention.

Thus, in a first aspect, the present invention provides a peptide ligand specific for IL-17, comprising a polypeptide and a molecular scaffold, the polypeptide comprising three residues selected from cysteine, L-2, 3-diaminopropionic acid (Dap), N- β -alkyl-L-2, 3-diaminopropionic acid (N-AlkDap) and N- β -haloalkyl-L-2, 3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of the three residues is selected from Dap, N-AlkDap or N-HAlkDap, the three residues being separated by at least two loop sequences, the peptide being linked to the scaffold via a covalent alkyl amino bond through the Dap or N-AlkDap or N-HAlkDap residue of the polypeptide and via a thioether bond through the cysteine residue of the polypeptide (when the three residues comprise cysteine), thereby forming two polypeptide loops on the molecular scaffold.

Suitably, the peptide ligand comprises an amino acid sequence selected from:

C_i-X₁-C_ii-X₂-C_iii

wherein:

C_i、C_iiand C_iiiIndependently cysteine, L-2, 3-diaminopropionic acid (Dap), N-beta-alkyl-L-2, 3-diaminopropionic acid (N-AlkDap) or N-beta-haloalkyl-L-2, 3-diaminopropionic acid (N-HAlkdap), with the proviso that C is_i、C_iiAnd C_iiiIs Dap, N-AlkDap or N-HAlkDap; and is

X₁And X₂Represents the amino acid sequence between cysteine, Dap, N-AlkDap or N-HAlkDap residues, wherein X₁And X₂Each independently a loop sequence of 3 to 7 amino acid residues.

The amino acid sequences of various specific peptide ligands according to the invention are defined in the appended claims.

It can be seen that the derivatives of the invention comprise a peptide loop coupled to a scaffold via at least one alkyl amino linkage (Dap or N-AlkDap linkage to the N-HAlkDap residue) and at most two thioether linkages (linkage to cysteine).

The prefix "alkyl" ("alkyl") in N-AlkDap and N-HAlkDap refers to an alkyl group having 1 to 4 carbon atoms, preferably a methyl group. The prefix "halo" is used in its normal meaning in this context to denote an alkyl group having one or more (suitably one) fluoro, chloro, bromo or iodo substituents.

When a cysteine is present, the thioether bond provides an anchor during formation of the cyclic peptide, as explained further below. In these embodiments, the thioether bond is suitably the central bond of the bicyclic peptide conjugate, i.e. the two residues forming the alkylamino bond in the peptide are spaced apart from and flanked by cysteine residues forming the thioether bond in the peptide sequence. In these preferred embodiments, the cyclic peptide structure is thus a bicyclic peptide conjugate having a central thioether linkage and two peripheral alkylamino linkages. In an alternative embodiment, the thioether bond is at the N-terminus or C-terminus of the peptide, and the central bond and the other terminal bond are selected from Dap, N-AlkDap, or N-HAlkDap.

In an embodiment of the invention, C_i、C_iiAnd C_iiiAll three of which may be Dap or N-AlkDap or N-hallkdap. In these embodiments, the peptide ligands of the invention are suitably bicyclic conjugates having a central alkylamino bond and two peripheral alkylamino bonds, the peptide forming two rings sharing the central alkylamino bond. In these and other embodiments, C_i、C_iiAnd C_iiiSuitably selected from N-AlkDap or N-hallkdap, most suitably N-AlkDap, because the reaction kinetics with the alkylated Dap is good.

Suitably, the peptide ligands of the invention are high affinity binders to human, mouse and canine IL-17, especially suitably to human IL-17. Suitably, binding affinity K to at least one target selected from hIL17-A, hIL17-E and/or hIL17-F_iLess than about 1000nM, less than about 500nM, less than about 100nM, less than about 50nM, or less than about 25 nM. Binding affinity in the context of the present specification refers to binding affinity determined by the method described below.

Suitably, the scaffold comprises a (hetero) aromatic or (hetero) alicyclic moiety, especially TBMB or TATA as further defined below.

In other aspects, the invention provides drug conjugates comprising a peptide ligand of the invention conjugated to one or more effectors and/or functional groups (such as a cytotoxic agent or a metal chelator). Suitably, the conjugate has a cytotoxic agent linked to the peptide ligand by a cleavable bond (such as a disulphide bond or a valine-citrulline bond). Suitably, the cytotoxic agent is selected from DM1 or MMAE.

According to a further aspect of the invention there is provided a pharmaceutical composition comprising a peptide ligand or drug conjugate as defined herein in combination with one or more pharmaceutically acceptable excipients.

According to a further aspect of the invention there is provided a peptide ligand or drug conjugate as defined herein for use in the prevention, inhibition or treatment of a disease or condition mediated by IL-17.

Drawings

Figure 1 shows a schematic structure of a reference bicyclic peptide ligand exhibiting specific binding to IL-17;

FIG. 2 shows a schematic structure of a first bicyclic peptide ligand according to the invention;

FIG. 3 shows a schematic structure of a second bicyclic peptide ligand according to the invention;

figure 4 shows a schematic structure of a third bicyclic peptide ligand according to the invention.

Figure 5 shows a schematic structure of a fourth bicyclic peptide ligand according to the invention;

figure 6 shows a schematic structure of a fifth bicyclic peptide ligand according to the invention;

figure 7 shows a schematic structure of a sixth bicyclic peptide ligand according to the present invention;

fig. 8 shows a schematic structure of a seventh bicyclic peptide ligand according to the present invention.

Detailed Description

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in the fields of peptide chemistry, cell culture and phage display, nucleic acid chemistry, and biochemistry). Standard techniques are used for Molecular Biology, genetics and biochemical procedures (see Sambrook et al, Molecular Cloning: A Laboratory Manual, 3 rd edition, 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al, Short Protocols in Molecular Biology (1999) 4 th edition, John Wiley & Sons, Inc.), which is incorporated herein by reference.

The invention provides a cyclic peptide structure as claimed in claim 1 comprising two peptide loops sandwiched between three bonds on a (protected between) molecular scaffold, the central bond being common to both loops. The central bond is a thioether bond with a cysteine residue of the peptide or an alkyl amino bond with a Dap or N-AlkDap or N-HalkDap residue of the peptide. The two outer bonds are suitably alkyl amino bonds with the Dap or N-AlkDap or N-HalkDap residue of the peptide, or one of the outer bonds may be a thioether bond with the cysteine residue of the peptide.

In one embodiment, the peptide ligands of the invention are fully cross-reactive with murine, canine, cynomolgus and human IL 17. In still other embodiments, the peptide ligands of the invention are selective for IL17-A, IL17-E and/or IL 17-F.

Suitably, the binding affinity, K, for at least one IL17, as determined by the methods described herein_iLess than about 1000nM, less than about 500nM, less than about 250nM, less than about 100nM, or less than about 50 nM.

The amino acid sequences of various specific peptide ligands according to the invention are defined in the appended claims.

When referring to amino acid residue positions within the bicyclic peptide compounds of the invention, the cysteine/Dap residue (C) is not changed_i、C_iiAnd C_iii) Omitted from the numbering, therefore, the amino acid residue numbers within representative bicyclic compounds are mentioned below:

-C_i-L₁-D₂-H₃-M₄-E₅-C_ii-R₆-G₇-D₈-M₉-D₁₀-C_iii-

suitably, the peptide may be cyclized with TBMB (1,3, 5-tris (bromomethyl) benzene) or 1,1' - (1,3, 5-triazinan-1, 3, 5-triyl) tripropyl-2-en-1-one (TATA) and results in a trisubstituted structure. Cyclization with TBMB and TATA occurs at C_i、C_iiAnd C_iii。

It is to be understood that modified derivatives of the peptide ligands as defined herein are also within the scope of the invention. Examples of such suitable modified derivatives include one or more modifications selected from: n-terminal and/or C-terminal modifications; substitution of one or more amino acid residues with one or more non-natural amino acid residues (e.g., substitution of one or more polar amino acid residues with one or more isosteric or isoelectronic amino acids; substitution of one or more non-polar amino acid residues with other non-natural isosteric or isoelectronic amino acids); adding a spacer group; replacing one or more oxidation-sensitive amino acid residues with one or more antioxidant amino acid residues; (ii) substitution of one or more amino acid residues with alanine, substitution of one or more L-amino acid residues with one or more D-amino acid residues; n-alkylation of one or more amide bonds within bicyclic peptide ligands; replacing one or more peptide bonds with alternative bonds; peptide backbone length modification; substitution of a hydrogen on the alpha-carbon of one or more amino acid residues with another chemical group, modification of amino acids (such as cysteine, lysine, glutamic acid/aspartic acid and tyrosine) with appropriate amine, thiol, carboxylic acid and phenol reagents to functionalize the amino acids, and introduction or substitution of amino acids that bring orthogonal reactivity suitable for functionalization, such as amino acids with azido or alkynyl groups, which respectively allow functionalization with alkyne or azide-bearing moieties.

In one embodiment, the modified derivative comprises an N-terminal and/or C-terminal modification. In other embodiments, wherein the modified derivative comprises an N-terminal modification using suitable amino reactive chemistry, and/or a C-terminal modification using suitable carboxy reactive chemistry. In other embodiments, the N-terminal or C-terminal modification comprises the addition of an effector group, including but not limited to a cytotoxic agent, a radio-chelator, or a chromophore.

In one embodiment, the N-terminal modification includes the addition of a molecular spacer group that facilitates conjugation of the effector group and retention of potency of the bicyclic peptide on its target. The spacer group is suitably an oligopeptide group containing from about 5 to about 30 amino acids, such as an Ala, G-Sar10-A or bAla-Sar10-A group. In one embodiment, the spacer group is selected from bAla-Sar 10-A.

For the purposes of this specification, N-terminal or C-terminal extensions of the bicyclic core sequence are added to the left or right side of the sequence, separated by hyphens. For example, the N-terminal β Ala-Sar10-Ala tail will be expressed as:

βAla-Sar10-A-(SEQ ID NO：X)

in one embodiment, the modified derivative comprises the substitution of one or more amino acid residues with one or more non-natural amino acid residues. In this embodiment, unnatural amino acids with isosteric/isoelectronic side chains can be selected that are neither recognized by degrading proteases nor have any adverse effect on target potency.

Alternatively, a limited number of applications may be usedSuch that proteolysis of nearby peptide bonds is conformationally and sterically hindered. In particular, these relate to proline analogues, bulky side chains, CDisubstituted derivatives (e.g. aminoisobutyric acid, Aib) and cyclic amino acids, the simple derivative being amino-cyclopropyl carboxylic acid.

In other embodiments, the unnatural amino acid residue is selected from: 1-naphthylalanine; 2-naphthylalanine; cyclohexylglycine, phenylglycine; tert-butyl glycine; 3, 4-dichlorophenylalanine; cyclohexylglycine; and homophenylalanine.

In still other embodiments, the unnatural amino acid residue is selected from: 1-naphthylalanine; 2-naphthylalanine and 3, 4-dichlorophenylalanine. These substitutions result in enhanced affinity compared to the unmodified wild-type sequence.

In still other embodiments, the unnatural amino acid residue is selected from: 1-naphthylalanine. This substitution provided the greatest level of affinity enhancement (greater than 7-fold) compared to the wild type.

In one embodiment, the modified derivative comprises the substitution of one or more oxidation-sensitive amino acid residues with one or more antioxidant amino acid residues. In other embodiments, the modified derivative comprises replacement of a tryptophan residue with a naphthylalanine or alanine residue. This embodiment provides the advantage of improving the drug stability profile of the resulting bicyclic peptide ligands.

In one embodiment, the modified derivative comprises the substitution of one or more charged amino acid residues with one or more hydrophobic amino acid residues. In an alternative embodiment, the modified derivative comprises the substitution of one or more hydrophobic amino acid residues with one or more charged amino acid residues. The correct balance of charged and hydrophobic amino acid residues is an important feature of bicyclic peptide ligands. For example, hydrophobic amino acid residues affect the degree of plasma protein binding and thus the concentration of free available moieties in plasma, while charged amino acid residues (in particular arginine) can affect the interaction of peptides with phospholipid membranes on cell surfaces. The combination of the two can affect the half-life, volume of distribution, and exposure of the peptide drug, and can be tailored to the clinical endpoint. In addition, the correct combination and number of charged amino acid residues and hydrophobic amino acid residues may reduce stimulation at the injection site (if the peptide drug has been administered subcutaneously).

In one embodiment, the modified derivative comprises the substitution of one or more L-amino acid residues with one or more D-amino acid residues. This embodiment is believed to be caused by steric hindrance as well as by D-amino acidsThe tendency to turn conformational stability to increase proteolytic stability (Tugyi et al (2005) PNAS, 102(2), 413-418).

In all peptide sequences defined herein, one or more tyrosine residues may be substituted by phenylalanine. This has been found to improve the yield of bicyclic peptide product during base-catalysed coupling of the peptide to the scaffold molecule.

In one embodiment, the modified derivative includes removal of any amino acid residue and substitution with alanine. This embodiment provides the advantage of removing potential proteolytic attack sites.

It should be noted that each of the above modifications is used to intentionally improve the efficacy or stability of the peptide. Further efficacy improvement based on modification can be achieved by the following mechanism:

-introducing hydrophobic moieties that exploit the hydrophobic effect and reduce the dissociation rate, thereby obtaining higher affinity;

introduction of charged groups, which utilize long range ionic interactions, leading to faster binding rates and higher affinities (see e.g. Schreiber et al Rapid, electronically associated association of proteins (1996), Nature struct. biol.3, 427-31); and

introducing additional constraints into the peptide, for example by correctly constraining the side chains of the amino acids such that the loss of entropy upon target binding is minimal, limiting the twist angle of the backbone such that the loss of entropy upon target binding is minimal, and introducing additional circularization in the molecule for the same reason.

(for review see Gentilucci et al, Current pharmaceutical Design, (2010), 16, 3185-.

The present invention includes all pharmaceutically acceptable (radio) isotopically-labeled compounds of the present invention, wherein one or more atoms are replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, and compounds of the present invention wherein an attached metal chelating group (referred to as an "effector") is capable of retaining the relevant (radio) isotope, as well as compounds of the present invention wherein certain functional groups are covalently substituted by the relevant (radio) isotope or isotopically-labeled functional group.

Examples of isotopes suitable for inclusion in compounds of the invention include isotopes of hydrogen, such as²H, (D) and³h (T); carbon, e.g.¹¹C，¹³C and¹⁴c; chlorine, e.g.³⁶Cl; fluorine, e.g.¹⁸F; iodine, e.g.¹²³I，¹²⁵I and¹³¹i; nitrogen, e.g.¹³N and¹⁵n; oxygen, e.g.¹⁵O，¹⁷O and¹⁸o; phosphorus, e.g.³²P; sulfur, e.g. of³⁵S; copper, e.g. of⁶⁴Cu; gallium, e.g.⁶⁷Ga or⁶⁸Ga; yttrium, e.g.⁹⁰Y and lutetium, e.g.¹⁷⁷Lu; and bismuth, e.g.²¹³Bi。

Certain isotopically-labeled compounds of the present invention, for example those into which a radioactive isotope has been introduced, are useful in drug and/or substrate tissue distribution studies, and in clinical assessment of the presence and/or absence of IL-17 targets on diseased tissues, such as tumors and other sites. The compounds of the invention may also have valuable diagnostic properties in that they can be used to detect or identify the formation of complexes between the marker compounds and other molecules, peptides, proteins, enzymes or receptors. The detection or identification method may use a compound labeled with a labeling agent, a labeling reagentSuch as radioisotopes, enzymes, fluorescent substances, luminescent substances (e.g., luminol derivatives, luciferin, aequorin, and luciferase), and the like. The radioactive isotope tritium (i.e. tritium) in view of its ease of introduction and ready means of detection³H (T)) and carbon-14 (i.e.¹⁴C) Particularly suitable for this purpose.

With heavier isotopes such as deuterium (i.e.²H (d) substitution may provide certain therapeutic advantages due to higher metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and may therefore be preferred in certain circumstances.

Using positron emitting isotopes (e.g. of the type¹¹C、¹⁸F、¹⁵O and¹³n) substitution can be used in Positron Emission Tomography (PET) studies to examine target occupancy.

Introduction of isotopes into metal-chelating effector groups (e.g. of⁶⁴Cu、⁶⁷Ga、⁶⁸Ga and¹⁷⁷lu), can be used to visualize tumor specific antigens using PET or SPECT imaging.

Introduction of isotopes into metal-chelating effector groups, such as but not limited to⁹⁰Y、¹⁷⁷Lu and²¹³bi, can provide an option for targeted radiotherapy, where the compounds of the invention with metal chelators deliver therapeutic radionuclides to the target protein and site of action.

Isotopically-labelled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples using an appropriate isotopically-labelled reagent in place of the unlabelled reagent previously used.

In the present context, specificity refers to the ability of a ligand to bind to or otherwise interact with its cognate target (excluding entities similar to the target). For example, specificity may refer to the ability of a ligand to inhibit human enzyme interactions, but not to inhibit homologous enzymes from different species. Using the methods described herein, the specificity can be modulated, i.e., increased or decreased, to enable the ligand to interact more or less with a homolog or paralog of the intended target. Specificity is not intended to be synonymous with activity, affinity or avidity, and the potency of an ligand's action on its target (e.g., binding affinity or inhibition level) is not necessarily related to its specificity.

Binding activity as used herein refers to a quantitative binding measurement obtained from a binding assay, e.g., as described herein. Thus, binding activity refers to the amount of peptide ligand bound at a given target concentration.

Multispecific is the ability to bind two or more targets. Generally, due to their conformational nature, binding peptides are capable of binding to a single target, such as an epitope in the case of an antibody. However, peptides can be developed that can bind two or more targets; for example, bispecific antibodies known in the art as described above. In the present invention, the peptide ligands are capable of binding two or more targets and are therefore multispecific. Suitably, it binds both targets, and is bispecific. Binding may be independent, meaning that the binding site on the peptide for the target is not structurally hindered by binding of one or the other of the targets. In this case, the two targets may bind independently. More generally, it is expected that binding of one target will at least partially block binding of another target.

There is a fundamental distinction between dual specific ligands and ligands with specificity that includes two related targets. In the first case, the ligands are specific for the two targets independently and interact with each target in a specific manner. For example, a first loop in the ligand may bind to a first target and a second loop may bind to a second target. In the second case, the ligand is non-specific in that it does not distinguish between the two targets, e.g., interacts with a target epitope common to both targets.

In the context of the present invention, ligands active against e.g. targets and orthologs may be bispecific ligands. However, in one embodiment, the ligand is not bispecific, but has a less precise specificity such that it binds the target and one or more orthologs. In general, ligands that are not selected for the target and its orthologs are unlikely to be bispecific due to lack of selection pressure for bispecific. The loop length in bicyclic peptides may be crucial in providing a tailored binding surface, such that good target and ortholog cross-reactivity can be obtained while maintaining high selectivity for less relevant homologues.

If the ligand is truly bispecific, in one embodiment, at least one of the ligand target specificities is common among the ligands selected, and the level of that specificity can be modulated by the methods disclosed herein. The second or more specificities need not be shared and need not be the subject of the procedures described herein.

The peptide ligand compounds of the present invention comprise, consist essentially of, or consist of a peptide covalently bound to a molecular scaffold. The term "scaffold" or "molecular scaffold" refers herein to a chemical moiety that is bonded to a peptide in a compound of the invention with an alkyl amino linkage and a thioether linkage (when a cysteine is present). The term "scaffold molecule" or "molecular scaffold molecule" refers herein to a molecule that is capable of reacting with a peptide or peptide ligand to form a derivative of the invention having alkylamino groups, and in certain embodiments, also thioether linkages. Thus, the scaffold molecule has the same structure as the scaffold moiety except that in the scaffold moiety the corresponding reactive group (e.g. leaving group) of the molecule is replaced by an alkylamino group and a thioether bond bonded to a peptide.

In embodiments, the scaffold is an aromatic molecular scaffold, i.e. a scaffold comprising (hetero) aryl groups. As used herein, "(hetero) aryl" is meant to include aromatic rings, e.g., 4-to 12-membered aromatic rings, such as benzene rings. These aromatic rings may optionally contain one or more heteroatoms (e.g., one or more of N, O, S and P), such as thienyl, pyridyl, and furyl rings. The aromatic ring may be optionally substituted. "(hetero) aryl" is also intended to include aromatic rings fused to one or more other aromatic or non-aromatic rings. For example, naphthyl, indolyl, thienothienyl, dithienothiophenyl and 5,6,7, 8-tetrahydro-2-naphthyl (each of which may be optionally substituted) are aryl groups for the purposes of this application. As noted above, the aromatic ring may be optionally substituted. Suitable substituents include alkyl (which may be optionally substituted), other aryl (which may themselves be substituted), heterocyclic (saturated or unsaturated), alkoxy (which is intended to include aryloxy (e.g., phenoxy), hydroxyl, aldehyde, nitro, amine (e.g., unsubstituted, or mono-or di-substituted with aryl or alkyl), carboxylic acid groups, carboxylic acid derivatives (e.g., carboxylic acid esters, amides, etc.), halogen atoms (e.g., Cl, Br, and I), and the like.

Suitably, the scaffold comprises a tri-substituted (hetero) aromatic or (hetero) alicyclic moiety, for example a tri-methylene substituted (hetero) aromatic or (hetero) alicyclic moiety. The (hetero) aromatic or (hetero) alicyclic moiety is suitably of six-membered ring structure, preferably trisubstituted, such that the scaffold has a 3-fold axis of symmetry.

In embodiments, the scaffold is a tri-methylene (hetero) aryl moiety, such as a1, 3, 5-trimethylenebenzene moiety. In these embodiments, the respective scaffold molecule suitably has a leaving group on the methylene carbon. The methylene group then forms R of the alkylamino bond as defined herein₁And (4) partial. In these methylene-substituted (hetero) aromatic compounds, the electron of the aromatic ring can stabilize the transition state during nucleophilic substitution. Thus, for example, the reactivity of benzyl halides for nucleophilic substitution is 100-fold 1000-fold higher than that of alkyl halides not attached to the (hetero) aromatic group.

In these embodiments, the scaffold and scaffold molecules have the general formula:

wherein LG represents a leaving group as further described below for the scaffold molecule, or LG (including R forming an alkylamino group)₁The adjacent methylene groups of the moiety) represent alkyl amino linkages to the peptide in the conjugate of the invention.

In embodiments, the group LG can be a halogen, such as, but not limited to, a bromine atom, in which case the scaffold molecule is 1,3, 5-tris (bromomethyl) benzene (TBMB). Another suitable molecular scaffold molecule is 2,4, 6-tris (bromomethyl) mesitylene. It is similar to 1,3, 5-tris (bromomethyl) benzene, but contains three additional methyl groups attached to the benzene ring. In the case of this scaffold, additional methyl groups can make further contact with the peptide, thus adding additional structural constraints. Thus, a different diversity range is achieved compared to 1,3, 5-tris (bromomethyl) benzene.

Another preferred molecule for forming a scaffold that reacts with a peptide by nucleophilic substitution is 1,3, 5-tris (bromoacetamido) benzene (TBAB):

in other embodiments, the scaffold is a non-aromatic molecular scaffold, such as a scaffold comprising a (hetero) alicyclic group. As used herein, "(hetero) alicyclic" refers to a saturated ring, either homo-or heterocyclic. The ring may be unsubstituted or may be substituted with one or more substituents. The substituents may be saturated or unsaturated, aromatic or non-aromatic, and examples of suitable substituents include those discussed above in connection with the substituents on the alkyl and aryl groups. Furthermore, two or more ring substituents may be combined to form another ring, and thus as used herein, "ring" is meant to include fused ring systems. In these embodiments, the cycloaliphatic scaffold is preferably 1,1' - (1,3, 5-triazinan-1, 3, 5-triyl) tripropyl-2-en-1-one (TATA).

In other embodiments, the molecular scaffold may have a tetrahedral geometry such that reaction of the four functional groups encoding the peptide with the molecular scaffold produces no more than two product isomers. Other geometries are possible; in fact, an almost unlimited number of scaffold geometries are possible, leading to a greater probability of diversification of peptide ligands.

The peptides used to form the ligands of the invention comprise Dap or N-AlkDap or N-HAlkDap residues for forming alkyl amino linkages bonded to the scaffold. The structure of diaminopropionic acid is similar to that of cysteine which has been used in the prior art to form thioether bonds with scaffolds, and is isosteric thereto, with the terminal-SH of cysteineradical-NH₂And (3) substitution:

the term "alkylamino" is used herein in its normal chemical sense to denote a group consisting of NH or N (R) bonded to two carbon atoms₃) Wherein the carbon atoms are independently selected from alkyl, alkylene or aryl carbon atoms, and R₃Is an alkyl group. Suitably, the alkylamino linkage of the present invention comprises an NH moiety bonded to two saturated carbon atoms, most suitably a methylene (-CH)₂-) carbon atoms. The alkylamino bond of the present invention has the general formula:

S–R₁–N(R₃)–R₂–P

wherein:

s represents a scaffold core, such as a (hetero) aromatic or (hetero) alicyclic ring, as further explained below;

R₁is a C1 to C3 alkylene group, suitably methylene or ethylene, most suitably methylene (CH)₂)；

R₂Methylene group of Dap or N-AlkDap side chain;

R₃is H or C1-4 alkyl, C1-4 alkyl includes branched alkyl and cycloalkyl groups, such as methyl, wherein any alkyl group is optionally halogenated; and is

P represents the peptide backbone, i.e. R of the above bond₂The moiety is attached to a carbon atom in the peptide backbone adjacent to the carboxyl carbon of the Dap or N-AlkDap or N-HAlkDap residue.

Certain bicyclic peptide ligands of the present invention have a number of advantageous properties that enable them to be considered suitable drug-like molecules for injection, inhalation, nasal, ocular, oral or topical administration. These advantageous properties include:

species cross-reactivity. This is a typical requirement for preclinical pharmacodynamic and pharmacokinetic assessments;

-protease stability. Bicyclic peptide ligands ideally should exhibit stability to plasma proteases, epithelial ("membrane-anchored") proteases, gastric and intestinal proteases, lung surface proteases, intracellular proteases, and the like. Protease stability should be maintained between different species so that bicyclic lead candidates can be developed in animal models and administered with confidence to humans;

-ideal solubility curve. This is a function of the ratio of charged hydrophilic residues to hydrophobic residues and intramolecular/intermolecular H bonds, which are important for formulation and absorption purposes; and

optimal plasma half-life in circulation. Depending on the clinical indication and treatment regimen, it may be desirable to develop bicyclic peptides for short-term exposure in an acute disease management setting, or to develop bicyclic peptides with enhanced retention in circulation, so as to be optimal for management of more chronic disease states. Other factors driving the ideal plasma half-life are the requirement for sustained exposure for maximum therapeutic efficiency, and the concomitant toxicology due to sustained exposure of the agent.

It is understood that salt forms are within the scope of the invention, and reference to peptide ligands of the invention includes salt forms of the compounds.

Salts of the invention may be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods, such as Pharmaceutical Salts: properties, Selection, and Use, p.heinrich Stahl (ed.), camile g.wermuth (ed.), ISBN: 3-90639-026-8, Hardcover, page 388, 8.2002. In general, these salts can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water, or in an organic solvent, or in a mixture of the two.

Acid addition salts (mono-or di-salts) may be formed using a variety of acids, both inorganic and organic. Examples of acid addition salts include mono-or di-salts with acids selected from: acetic acid, 2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphorsulfonic acid, (+) - (1S) -camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, hemi-lactic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (e.g., D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), alpha-oxoglutaric acid, glycolic acid, hippuric acid, hydrohalic acid (e.g., hydrobromic acid, hydrochloric acid, hydroiodic acid), Isethionic acid, lactic acid (e.g., (±) -DL-lactic acid), lactobionic acid, maleic acid, malic acid, (-) -L-malic acid, malonic acid, (±) -DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1, 5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, pyruvic acid, L-pyroglutamic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+) -L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid and valeric acid, and acylated amino acids and cation exchange resins.

One particular group of salts consists of salts formed from the following acids: acetic acid, hydrochloric acid, hydroiodic acid, phosphoric acid, nitric acid, sulfuric acid, citric acid, lactic acid, succinic acid, maleic acid, malic acid, isethionic acid, fumaric acid, benzenesulfonic acid, toluenesulfonic acid, sulfuric acid, methanesulfonic acid (methanesulfonate), ethanesulfonic acid, naphthalenesulfonic acid, valeric acid, propionic acid, butyric acid, malonic acid, glucuronic acid and lactobionic acid. One specific salt is the hydrochloride salt. Another specific salt is acetate.

If the compound is an anionic compound, or has a functional group which may be anionic (for example, -COOH may be-COO)^-) Salts may be formed with organic or inorganic bases to produce suitable cations. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Li⁺、Na⁺And K⁺Alkaline earth metal cations such as Ca²⁺And Mg²⁺And other cations such as Al³⁺Or Zn⁺. Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH)₄ ⁺) And substituted ammonium ions (e.g. NH)₃R⁺、NH₂R₂ ⁺、NHR₃ ⁺、NR₄ ⁺). Some examples of suitable substituted ammonium ions areThose derived from: methylamine, ethylamine, diethylamine, propylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine and tromethamine, and amino acids such as lysine and arginine. An example of a common quaternary ammonium ion is N (CH)₃)₄ ⁺。

When the compounds of the invention contain amine functionality, these may form quaternary ammonium salts, for example by reaction with alkylating agents according to methods well known to those skilled in the art. Such quaternary ammonium compounds are within the scope of the present invention.

According to the present invention, several conjugated peptides may be incorporated together into the same molecule. For example, two such peptide conjugates with the same specificity can be linked together by a molecular scaffold, increasing the affinity of the derivative for its target. Alternatively, in another embodiment, multiple peptide conjugates are combined to form a multimer. For example, two different peptide conjugates are combined to form a multispecific molecule. Alternatively, three or more peptide conjugates, which may be the same or different, may be combined to form a multispecific derivative. In one embodiment, multivalent complexes can be constructed by linking together molecular scaffolds, which may be the same or different.

The peptide ligands of the invention may be prepared by a process comprising: providing suitable peptides and scaffold molecules; and formation of thioether (when cysteine is present) and alkylamino bonds between the peptide and the scaffold molecule.

Peptides for use in preparing the peptide ligands of the invention may be prepared from amino acid starting materials using conventional solid phase synthesis, which may include appropriate protecting groups as described herein. Such methods for preparing peptides are well known in the art.

Suitably, the peptide has a protecting group on a nucleophilic group other than-SH and the amine group used to form the alkylamino bond. Several studies have been carried out on the nucleophilicity of the amino acid side chains, listed in descending order: thiol esters (thiolates) in cysteine, amines in lysine, secondary amines in histidine and tryptophan, guanidinamine in arginine, hydroxyl groups in serine/threonine, and finally carboxylates in aspartic acid and glutamic acid. Thus, in some cases, it may be desirable to apply protecting groups to more nucleophilic groups on peptides to prevent unwanted side reactions with these groups.

In an embodiment, a method comprises: synthesizing a peptide having a protecting group on a nucleophilic group in addition to an amine group for forming an alkylamino bond and a second protecting group on an amine group for forming an alkylamino bond, wherein the protecting group on the amine group for forming an alkylamino bond can be removed under conditions different from the protecting groups used on other nucleophilic groups, and then treating the peptide under conditions selected to deprotect the amine group for forming an alkylamino bond without deprotecting the other nucleophilic groups. Then, a coupling reaction with the scaffold is performed, and then the remaining protecting group is removed to obtain a peptide conjugate.

Suitably, the method comprises reacting a peptide having a reactive side chain-SH and an amine group with a scaffold molecule having three or more leaving groups in a nucleophilic substitution reaction.

The term "leaving group" is used herein in its normal chemical sense to mean a moiety capable of nucleophilic substitution by an amine group. Any such leaving group may be used herein provided that it is readily removed by nucleophilic substitution of the amine. Suitable leaving groups are the conjugate bases of acids having a pKa of less than about 5. Non-limiting examples of leaving groups for use in the present invention include halogens such as bromine, chlorine, iodine, O-tosylate (OTos), O-mesylate (OMes), O-triflate (OTf), or O-trimethylsilyl (OTMS).

The nucleophilic substitution reaction may be carried out in the presence of a base, for example, wherein the leaving group is a conventional anionic leaving group. The inventors of the present invention have found that by appropriate selection of the solvent and base (and pH) used for the nucleophilic substitution reaction, the yield of cyclized peptide ligand can be greatly improved, and further, the preferred solvent and base are different from the prior art combinations involving only thioether bond formation. In particular, the inventors of the present invention found that improved yields are achieved when trialkylamine bases are used, said yieldsTrialkylamine base is of formula NR₁R₂R₃Wherein R is₁、R₂And R₃Independently, a C1-C5 alkyl group, suitably a C2-C4 alkyl group, specifically a C2-C3 alkyl group. Particularly suitable bases are triethylamine and Diisopropylethylamine (DIPEA). These bases have only a weak nucleophilic property, and this property is believed to result in fewer side reactions and higher yields observed with these bases. The inventors of the present invention have further found that preferred solvents for nucleophilic substitution reactions are polar and protic solvents, in particular containing MeCN and H in a volume ratio of 1:10 to 10:1₂MeCN/H of O₂O, suitably in the range of from 2:10 to 10:2, more suitably from 3:10 to 10:3, in particular from 4:10 to 10: 4.

Additional binding or functional activity can be attached to the N-or C-terminus of the peptide covalently linked to the molecular scaffold. The functional group is for example selected from: a group capable of binding to a molecule that extends the half-life of the peptide ligand in vivo, and a molecule that extends the half-life of the peptide ligand in vivo. Such a molecule may be, for example, HSA or a cell matrix protein, and the group capable of binding to a molecule that extends the half-life of the peptide ligand in vivo is an antibody or antibody fragment specific for HSA or a cell matrix protein. Such molecules may also be conjugates with high molecular weight PEG.

In one embodiment, the functional group is a binding molecule selected from the group consisting of a second peptide ligand comprising a peptide covalently linked to a molecular scaffold, and an antibody or antibody fragment. 2. 3,4, 5 or more peptide ligands may be linked together. The specificity of any two or more of these derivatives may be the same or different; if they are the same, a multivalent binding structure will be formed, which has increased affinity for the target compared to a monovalent binding molecule. In addition, the molecular scaffolds may be the same or different, and may entrap (subcontend) the same or different number of rings.

Furthermore, the functional group may be an effector group, such as an antibody Fc region.

The attachment to the N or C terminus may be performed before or after the peptide is bound to the molecular scaffold. Thus, peptides can be produced (synthetically, or by biologically derived expression systems) in which an N-or C-terminal peptide group is already present. Preferably, however, the addition to the N-or C-terminus is performed after the peptide is combined with the molecular scaffold to form a conjugate. For example, fluorenylmethoxycarbonyl chloride may be used to introduce an Fmoc protecting group at the N-terminus of the peptide. Fmoc binds serum albumin including HSA with high affinity and Fmoc-Trp or Fmoc-Lys binds with increased affinity. The peptide may be synthesized with the Fmoc protecting group retained and then coupled to the scaffold via an alkylamino group. Another option is a palmitoyl moiety that also binds HSA and has been used, for example, in Liraglutide (Liraglutide) to prolong the half-life of this GLP-1 analogue.

Alternatively, a conjugate of the peptide with the scaffold can be prepared and then modified at the N-terminus, for example by reacting the linker with an amine and thiol for N-e-maleimidohexanoic acid) succinimidyl Ester (EMCS). Through this linker, the peptide conjugate can be linked to other peptides, such as an antibody Fc fragment.

The binding function may be another peptide that binds to the molecular scaffold to produce a multimer; another binding protein, including an antibody or antibody fragment; or any other desired entity, including serum albumin or effector groups, such as antibody Fc regions.

Furthermore, additional binding or functional activity may be directly bound to the molecular scaffold.

In embodiments, the scaffold may further comprise reactive groups to which additional activity may be bound. Preferably, this group is orthogonal with respect to other reactive groups on the molecular scaffold to avoid interaction with the peptide. In one embodiment, the reactive group may be protected and deprotected if necessary to conjugate additional activity.

Accordingly, in a further aspect of the invention there is provided a drug conjugate comprising a peptide ligand as defined herein conjugated to one or more effectors and/or functional groups.

The effector and/or functional group may be attached, for example, to the N or C terminus of the polypeptide, or to a molecular scaffold.

Suitable effector groups include antibodies and portions or fragments thereof. For example, the effector group may include an antibody light chain constant region (CL), an antibody CH1 heavy chain domain, an antibody CH2 heavy chain domain, an antibody CH3 heavy chain domain, or any combination thereof, in addition to one or more constant region domains. The effector group may also comprise the hinge region of an antibody (such a region is typically found between the CH1 and CH2 domains of an IgG molecule).

In other embodiments of this aspect of the invention, the effector group according to the invention is an Fc region of an IgG molecule. Advantageously, the peptide ligand-effector group according to the invention comprises or consists of a peptide ligand Fc fusion having a t β half-life of 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, or 7 days or more. Most advantageously, the peptide ligand according to the invention comprises or consists of a peptide ligand Fc-fusion having a t β half-life of 1 day or more.

Functional groups typically include binding groups, drugs, reactive groups for attachment of other entities, functional groups that facilitate uptake of the macrocyclic peptide into a cell, and the like.

The ability of the peptide to penetrate into the cell will render the peptide effective against the target within the cell. Targets that can be accessed by peptides with the ability to penetrate into cells include transcription factors, intracellular signaling molecules such as tyrosine kinases, and molecules involved in apoptotic pathways. Functional groups capable of penetrating cells include peptides or chemical groups that have been added to a peptide or molecular scaffold. Such as peptides derived from VP22, HIV-Tat, Drosophila's homeobox protein (antennapedia), etc., e.g.such as Chen and Harrison, Biochemical Society Transactions (2007) Vol.35, part 4, page 821; gupta et al, Advanced Drug Discovery Reviews (2004), volume 57 9637. Examples of short peptides that have been shown to be efficiently translocated through the plasma membrane include the 16 amino acid penetrating peptide from drosophila antennapedia protein (desrossi et al (1994) J biol. chem. 269, p. 10444), the 18 amino acid 'model amphipathic peptide' (Oehlke et al (1998) Biochim biophysis Acts, p. 1414, p. 127), and the arginine-rich region of the HIV TAT protein. Non-peptide Methods include the use of small molecule mimetics or SMOCs that can be easily attached to biomolecules (Okuyama et al (2007) Nature Methods, vol 4, page 153). Other chemical strategies to add guanidine groups to the molecule also enhance cell penetration (Elson-Scwab et al (2007) J Biol Chem, Vol.282, p.13585). Small molecular weight molecules (e.g., steroids) can be added to the molecular scaffold to enhance cellular uptake.

One class of functional groups that can be attached to a peptide ligand includes antibodies and binding fragments thereof, such as Fab, Fv or single domain fragments. In particular, antibodies can be used which bind to proteins capable of increasing the half-life of the peptide ligand in vivo.

In one embodiment, the peptide ligand-effector group according to the invention has a t β half-life selected from: 12 hours or more, 24 hours or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, 14 days or more, 15 days or more, or 20 days or more. Advantageously, the peptide ligand-effector group or composition according to the invention will have a t β half-life of 12 to 60 hours. In other embodiments, it has a t β half-life of one day or more. In still other embodiments, the half-life is from 12 to 26 hours.

In a particular embodiment of the invention, the functional group conjugated to the cyclic peptide is selected from metal chelators, which are suitable for complexing pharmaceutically relevant metal radioisotopes. When complexed with the radioisotope, these effectors may provide useful agents for cancer therapy. Suitable examples include DOTA, NOTA, EDTA, DTPA, HEHA, SarAR, etc. (Targeted radiationalcide therapy, to Speer, Wolters/Kluver Lippincott Williams & Wilkins, 2011).

Possible effector groups also include enzymes such as carboxypeptidase G2 for enzyme/prodrug therapy, in which a peptide ligand is substituted for an antibody in ADEPT.

In a particular embodiment of this aspect of the invention, the functional group is selected from drugs, such as cytotoxic agents for cancer therapy. Suitable examples include: alkylating agents, such as cisplatin and carboplatin, and oxaliplatin, dichloromethyldiethylamine, cyclophosphamide, chlorambucil, ifosfamide; antimetabolites include the purine analogs azathioprine and mercaptopurine or pyrimidine analogs; plant alkaloids and terpenoids include vinca alkaloids, such as vincristine, vinblastine, vinorelbine, and vindesine; etoposide and teniposide, which are derivatives of podophyllotoxin; taxanes, including paclitaxel, originally called Taxol; topoisomerase inhibitors include camptothecin: irinotecan and topotecan, and type II inhibitors, including amsacrine, etoposide phosphate, and teniposide. Other agents may include antitumor antibiotics including the immunosuppressive agents actinomycin D (for kidney transplantation), doxorubicin, epirubicin, bleomycin, and the like.

In a further specific embodiment of the invention according to this aspect, the cytotoxic agent is selected from DM1 or MMAE.

DM1 is a cytotoxic agent, which is a thiol-containing derivative of maytansine, having the following structure:

monomethyl auristatin e (mmae) is a synthetic antitumor agent with the following structure:

in one embodiment, the cytotoxic agent is linked to the bicyclic peptide through a cleavable bond (e.g., a disulfide bond). In other embodiments, groups adjacent to the disulfide bonds are modified to control the blockage of the disulfide bonds and thereby control the rate of cleavage and concomitant release of the cytotoxic agent.

Published work establishes the potential to modify the susceptibility of disulfide bonds to reduction by introducing steric hindrance on either side of the disulfide bond (Kellogg et al (2011) Bioconjugate Chemistry, 22, 717). Greater steric hindrance reduces the rate of reduction of intracellular glutathione and extracellular (systemic) reducing agents, thereby reducing the ease with which toxins are released both intracellularly and extracellularly. Thus, by carefully selecting the degree of hindrance on either side of the disulfide bond, an optimal choice of disulfide stability in circulation (minimizing undesirable side effects of the toxin) and efficient release in the intracellular environment (maximizing therapeutic effect) can be achieved.

Blocking on either side of the disulfide bond is modulated by introducing one or more methyl groups on the targeting entity (here, a bicyclic peptide) or toxin side of the molecular construct.

Thus, in one embodiment, the cytotoxic agent is selected from a compound of the formula:

wherein n represents an integer selected from 1 to 10; and is

R₁And R₂Independently represents hydrogen or methyl.

In one embodiment of the compounds of the above formula, n represents 1, R₁And R₂All represent hydrogen (i.e. maytansine derivative DM 1).

In an alternative embodiment of the compounds of the above formula, n represents 2, R₁Represents hydrogen and R₂Represents methyl (i.e. maytansine derivative DM 3).

In one embodiment of the compound, n represents 2, R₁And R₂All represent methyl (i.e. maytansine derivative DM 4).

It is understood that cytotoxic agents can form disulfide bonds and that disulfide linkages between thiol-toxins and thiol-bicyclic peptides are introduced by several possible synthetic schemes in the structure of conjugates with bicyclic peptides.

In one embodiment, the bicyclic peptide component of the conjugate has the following structure:

wherein m represents an integer selected from 0 to 10,

bicyclic represents any suitable cyclic peptide structure as described herein; and is

R₃And R₄Independently represents hydrogen or methyl.

Wherein R is₃And R₄Compounds of the above formula, in which both are hydrogen, are considered unhindered, and wherein R is₃And R₄Compounds of the above formula in which one or all represent methyl groups are considered hindered.

It is understood that bicyclic peptides of the above formula can form disulfide bonds and that disulfide linkages between thiol-toxins and thiol-bicyclic peptides can be introduced by several possible synthetic schemes in the above-described conjugate structures with cytotoxic agents.

In one embodiment, the cytotoxic agent is linked to the bicyclic peptide through the following linker:

wherein R is₁、R₂、R₃And R₄Represents hydrogen or C1-C6 alkyl;

toxin refers to any suitable cytotoxic agent as defined herein;

bicyclic represents any suitable cyclic peptide structure as described herein;

n represents an integer selected from 1 to 10; and is

m represents an integer selected from 0 to 10.

When R is₁、R₂、R₃And R₄With each hydrogen, the disulfide bond is least hindered and most easily reduced. When R is₁、R₂、R₃And R₄When each is alkyl, the disulfide bond is most hindered and least easily reduced. Partial substitution of hydrogen and alkyl groups results in a gradual increase in reduction tolerance, with concomitant toxin cleavage and release. Preferred embodiments include: r₁、R₂、R₃And R₄Are all H; r₁、R₂、R₃Are all H and R₄Methyl group; r₁、R₂Methyl, R₃、R₄＝H；R₁、R₃Methyl, R₂、R₄H; and R₁、R₂＝H，R₃、R₄C1-C6 alkyl.

In one embodiment, the toxin of the compound is maytansine and the conjugate comprises a compound of the formula:

wherein R is₁、R₂、R₃And R₄As defined above;

bicyclic represents any suitable cyclic peptide structure as defined herein;

n represents an integer selected from 1 to 10; and is

m represents an integer selected from 0 to 10.

Further details and methods for preparing conjugates of the aforementioned bicyclic peptide ligands with toxins are described in detail in our published patent applications WO2016/067035 and WO 2017/191460. The entire disclosures of these applications are expressly incorporated herein by reference.

The linker between the toxin and the bicyclic peptide can comprise a triazole group formed by a click chemistry reaction between the azide-functionalized toxin and the alkyne-functionalized bicyclic peptide structure (or vice versa). In other embodiments, the bicyclic peptide can contain an amide bond formed by the reaction between a carboxylic acid functionalized toxin and the N-terminal amino group of the bicyclic peptide.

The linker between the toxin and the bicyclic peptide may comprise a cathepsin-cleavable group to provide selective release of endotoxin from the target cell. A suitable cathepsin-cleavable group is valine-citrulline.

The linker between the toxin and the bicyclic peptide may comprise one or more spacer groups to provide a desired function, e.g., binding affinity for the conjugate or cathepsin cleavability. A suitable spacer group is p-aminobenzyl carbamate (PABC), which may be located intermediate to the valine-citrulline group and the toxin moiety.

Thus, in embodiments, the bicyclic peptide-drug conjugate may have the following structure consisting of toxin-PABC-cit-val-triazole-bicyclic:

in other embodiments, the bicyclic peptide-drug conjugate may have the following structure consisting of toxin-PABC-cit-val-dicarboxylate-bicyclo:

wherein (alk) is of formula C_nH_2nWherein n is 1 to 10, may be straight or branched chain, suitably (alk) is n-propylene or n-butylene.

Detailed descriptions of methods for preparing peptide ligand-drug conjugates according to the present invention are given in our prior applications WO2016/067035 and PCT/EP2017/083954 filed on 12/20/2017, the entire contents of which are incorporated herein by reference.

The peptide ligands according to the invention are useful in vivo therapeutic and prophylactic applications, in vitro and in vivo diagnostic applications, in vitro assay and reagent applications, and the like.

In general, the use of peptide ligands may replace the use of antibodies. The derivatives selected according to the invention are used diagnostically in western blot analysis and in situ protein detection by standard immunohistochemical procedures; for use in these applications, derivatives of the selected library may be labeled according to techniques known in the art. Furthermore, when complexed with a chromatographic support (e.g., a resin), these peptide ligands can be used for preparation in an affinity chromatography step. All of these techniques are well known to those skilled in the art. The peptide ligands according to the invention have similar binding capacity as antibodies and can be substituted for antibodies in such assays.

Diagnostic uses include any use to which antibodies are commonly applied, including test strip assays, laboratory assays, and immunodiagnostic assays.

Therapeutic and prophylactic uses of the peptide ligands prepared according to the invention include administration of a derivative selected according to the invention to a recipient mammal (e.g., a human). Preferably at least 90% to 95% homogeneity of the substantially pure peptide ligand for administration to a mammal, most preferably 98% to 99% or more homogeneity for pharmaceutical use, particularly when the mammal is a human. Once purified, partially purified or to homogeneity as desired, the selected peptides can be used for diagnosis or therapy (including in vitro) or in development and performance of assay procedures, immunofluorescent staining, etc. (Lefkovite and Pernis, (1979 and 1981) Immunological Methods, Vol.I and II, Academic Press, NY).

Typically, the peptide ligands of the invention will be used in purified form together with a pharmacologically suitable carrier. Typically, these carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, any carrier including salts and/or buffer media. Parenteral vehicles (vehicles) include sodium chloride solution, ringer's dextrose, dextrose and sodium chloride, and lactated ringer's solution. Suitable physiologically acceptable adjuvants (if necessary to keep the peptide complex in suspension) may be selected from thickening agents such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates.

Intravenous vehicles include liquid and nutritional supplements and electrolyte supplements such as those based on ringer's dextrose. Preservatives and other additives may also be present, such as antimicrobials, antioxidants, chelating agents and inert gases (Mack (1982) Remington's Pharmaceutical Sciences, 16 th edition).

The peptide ligands of the invention may be used as separately administered compositions or in combination with other agents. These agents may include antibodies, antibody fragments, and various immunotherapeutic drugs, such as cyclosporine, methotrexate, doxorubicin or cisplatin, and immunotoxins. The pharmaceutical compositions may include "cocktails" of various cytotoxic or other agents in combination with selected antibodies, receptors or binding proteins thereof of the invention, or even combinations of selected peptides of the invention having different specificities, such as peptides selected using different target derivatives, whether or not they are combined prior to administration.

The route of administration of the pharmaceutical composition according to the present invention may be any one known to those of ordinary skill in the art. For treatment, including but not limited to immunotherapy, the selected antibodies, receptors, or binding proteins thereof of the invention can be administered to any patient according to standard techniques. Administration may be by any suitable means, including parenterally, intravenously, intramuscularly, intraperitoneally, transdermally, by pulmonary route, or also by direct infusion with a catheter as appropriate. The dose and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, contraindications (counter-indication) and other parameters that should be considered by the clinician.

The peptide ligands of the invention may be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has proven effective and lyophilization and reconstitution techniques known in the art can be employed. Those skilled in the art will appreciate that lyophilization and reconstitution can result in varying degrees of loss of activity, and that usage levels may have to be adjusted upward to compensate.

Compositions containing the peptide ligands of the invention or mixtures thereof may be administered for prophylactic and/or therapeutic treatment. In certain therapeutic applications, a sufficient amount to achieve at least partial inhibition, suppression, modulation, killing, or some other measurable parameter of a selected cell population is defined as a "therapeutically effective dose". The amount required to achieve this dose will depend on the severity of the disease and the general state of the patient's own immune system, but will generally range from 0.005 to 5.0mg of the selected peptide ligand per kilogram of body weight, with doses of from 0.05 to 2.0 mg/kg/dose being more commonly used. For prophylactic applications, compositions containing the peptide ligands of the invention or mixtures thereof may also be administered at similar or slightly lower doses.

Peptide ligands selected according to the methods of the invention are useful for in vivo therapeutic and prophylactic applications, in vitro and in vivo diagnostic applications, in vitro assay and reagent applications, and the like. Ligands with selected levels of specificity may be used in applications involving testing in non-human animals where cross-reactivity is desired, or in diagnostic applications where careful control of cross-reactivity with homologues or paralogs is desired. In some applications, such as vaccine applications, the ability to elicit an immune response to a predetermined range of antigens can be exploited to tailor vaccines against specific diseases and pathogens.

Preferably at least 90% to 95% homogeneity of the substantially pure peptide ligand for administration to a mammal, most preferably 98% to 99% or more homogeneity for pharmaceutical use, particularly when the mammal is a human. Once purified, partially purified or to homogeneity as desired, the selected polypeptide may be used for diagnosis or therapy (including in vitro) or for development and performance of assay procedures, immunofluorescent staining and the like (Lefkovite and Pernis, (1979 and 1981) Immunological Methods, Vol.I and II, Academic Press, NY).

The bicyclic peptides of the invention have particular utility as binders to IL-17 (e.g., IL-17A, IL-17E and IL-17F).

According to a further aspect of the invention there is provided a peptide ligand or drug conjugate as defined herein for use in the prevention, inhibition or treatment of a disease or condition mediated by IL-17.

According to a further aspect of the invention there is provided a method of preventing, inhibiting or treating a disease or disorder mediated by IL-17 comprising administering to a patient in need thereof an effector group of a peptide ligand as defined herein and a drug conjugate.

In one embodiment, the IL-17 is a mammalian IL-17. In other embodiments, the mammalian IL-17 is a human IL-17.

In one embodiment, the disease or disorder mediated by IL-17 is selected from the group consisting of inflammatory disorders and cancer. In other embodiments, the disease or disorder mediated by IL-17 is selected from the group consisting of: rheumatoid Arthritis (RA), bone erosion, intraperitoneal abscesses, inflammatory bowel disease, allograft rejection, psoriasis, angiogenesis, atherosclerosis, asthma, multiple sclerosis, Systemic Lupus Erythematosus (SLE), ocular surface diseases (e.g., dry eye), ankylosing spondylitis, psoriatic arthritis, cancer (e.g., multiple myeloma and breast cancer).

In other embodiments, the disease or disorder mediated by IL-17 is selected from cancer.

Examples of cancers (and their benign counterparts) that can be treated (or inhibited) include, but are not limited to, tumors of epithelial origin (various types of adenomas and carcinomas, including adenocarcinomas, squamous carcinomas, transitional cell carcinomas, and other carcinomas), such as bladder and urinary tract cancers, breast cancers, gastrointestinal cancers (including esophagus, stomach, small intestine, colon, rectum, and anus), liver cancers (hepatocellular carcinoma), carcinomas of the gallbladder and biliary tract, exocrine pancreatic cancers, kidney cancers, lung cancers (e.g., adenocarcinoma, small cell lung cancer, non-small cell lung cancer, bronchioloalveolar cancer, and mesothelioma), head and neck cancers (e.g., tongue, oral, larynx, pharynx, nasopharynx, tonsil, salivary gland, nasal cavity, and paranasal sinus cancers), ovarian cancers, fallopian tube cancers, peritoneal cancers, vaginal cancers, vulval cancers, penile cancers, cervical cancers, myometrial cancers, thyroid cancers (e.g., thyroid follicular cancer), Adrenal cancer, prostate cancer, skin and adnexal cancers (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dysplastic nevi); hematologic malignancies (i.e., leukemia, lymphoma) and diseases of premalignant hematologic and marginal malignancies include hematologic malignancies and disorders associated with the lymphatic system (e.g., acute lymphocytic leukemia [ ALL ], chronic lymphocytic leukemia [ CLL ], B-cell lymphomas such as diffuse large B-cell lymphoma [ DLBCL ], follicular lymphoma, Burkitt's lymphoma, mantle cell lymphoma, T-cell lymphoma and leukemia, Natural killer [ NK ] cell lymphoma, Hodgkin's lymphoma, hairy cell leukemia, nonsignificant monoclonal gammoproteinemia, plasmacytoma, multiple myeloma, and post-transplant lymphoproliferative disorders), and hematologic malignancies and disorders associated with the bone marrow system (e.g., acute myelogenous leukemia [ AML ], chronic myelogenous leukemia [ CML ], chronic myelogenous leukemia [ ML ], "CML Eosinophilic syndrome, myeloproliferative disorders such as polycythemia vera, primary thrombocythemia and primary myelofibrosis, myeloproliferative syndrome, myelodysplastic syndrome and promyelocytic leukemia); tumors of mesenchymal origin, for example sarcomas of soft tissue, bone or cartilage such as osteosarcoma, fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, angiosarcoma, kaposi's sarcoma, ewing's sarcoma, synovial sarcoma, epithelioid sarcoma, gastrointestinal stromal tumors, benign and malignant tissue cell tumors, and dermatofibrosarcoma protruberans; tumors of the central or peripheral nervous system (e.g., astrocytomas, gliomas and glioblastomas, meningiomas, ependymomas, pinealomas, and schwannomas); endocrine tumors (e.g., pituitary tumors, adrenal tumors, islet cell tumors, parathyroid tumors, carcinoid tumors, and medullary thyroid cancers); ocular and accessory tumors (e.g., retinoblastoma); germ cell and trophoblastic tumors (e.g., teratoma, seminoma, dysgerminoma, hydatidiform mole, and choriocarcinoma); and pediatric and embryonic tumors (e.g., medulloblastoma, neuroblastoma, wilms tumor, and primitive neuroectodermal tumors); or congenital or other syndromes that predispose a patient to a malignancy (e.g., xeroderma pigmentosum).

In one embodiment, the disease or disorder mediated by IL-17 is a disease or disorder mediated by IL-17A. In other embodiments, the peptide ligand is specific for IL-17A as defined herein, and the disease or disorder mediated by IL-17 is a disease or disorder mediated by IL-17A. In other embodiments, the disease or disorder mediated by IL-17A is selected from airway inflammatory diseases and psoriasis.

In one embodiment, the disease or disorder mediated by IL-17 is a disease or disorder mediated by IL-17E. In other embodiments, the peptide ligand is specific for IL-17E as defined herein, and the disease or disorder mediated by IL-17 is a disease or disorder mediated by IL-17E. In other embodiments, the disease or disorder mediated by IL-17A is selected from airway inflammatory diseases.

In one embodiment, the disease or disorder mediated by IL-17 is a disease or disorder mediated by IL-17F. In other embodiments, the peptide ligand is specific for IL-17F as defined herein, and the disease or disorder mediated by IL-17 is a disease or disorder mediated by IL-17F. In other embodiments, the disease or disorder mediated by IL-17F is selected from the group consisting of airway inflammatory diseases and psoriasis.

Reference herein to the term "prevention" relates to the administration of a protective composition prior to the induction of disease. By "inhibit" is meant administration of the composition after the induction event but before clinical occurrence of the disease. "treatment" refers to the administration of a protective composition after symptoms of the disease become apparent.

Animal model systems are available that can be used to screen peptide ligands for effectiveness in protecting against or treating a disease. The present invention facilitates the use of animal model systems that allow the development of polypeptide ligands that are cross-reactive with human and animal targets to allow the use of animal models.

The invention is further described with reference to the following examples.

Examples

Peptide synthesis

Peptide synthesis was performed based on the Fmoc chemistry method using a Symphony Peptide synthesizer manufactured by Peptide Instruments and a Syro II synthesizer manufactured by MultiSynTech. Standard Fmoc-amino acids (Sigma, Merck) were used, with appropriate side chain protecting groups: in each case using standard coupling conditions, and then using standard methods for deprotection. Unless otherwise indicated, all amino acids are used in the L-configuration. The peptide was purified using HPLC and modified after isolation with 1,3, 5-tris (bromomethyl) benzene (TBMB, Sigma). For this purpose, the linear peptide is treated with H₂O to about 35mL, add about 500. mu.l of 100mM TBMB in acetonitrile and add 5mL of 1M NH₄HCO₃H of (A) to (B)₂The reaction is initiated by the O solution. The reaction was carried out at room temperature for about 30 to 60 minutes and was lyophilized once the reaction was complete (as judged by MALDI). After lyophilization, the modified peptide was purified as described above while replacing Luna C8 with a Gemini C18 column (Phenomenex) and changing the acid to 0.1% trifluoroacetic acid. Pure fractions containing the correct TMB modifying substance were pooled, lyophilized and stored at-20 ℃.

The following unnatural amino acid precursors were used to make DAP and N-MeDAP modified peptides:

compound (I)	CAS	Mw	Suppliers of goods
				Fmoc-L-Dap(Boc,Me)-OH	446847-80-9	440.49	Iris Biotech GMBH
Fmoc-Dap(Boc)-OH	162558-25-0	426.46	Sigma Aldrich

IL-17A, IL-17E and IL-17F binding assays

IL-17A, IL-17E and IL-17F binding was determined using a method similar to that described in WO 2011/141823.

The peptide ligands of the examples and reference examples were tested in the above assay.

Reference example 1

The first reference bicyclic peptide chosen for comparison of thioether to alkylamino scaffold linkages was designated BCY 00008655. It is a bicyclic conjugate of a thioether-forming peptide with a trimethylene benzene scaffold, wherein the peptide comprises three cysteine residues. The structure of the bicyclic derivative is schematically shown in fig. 1. The linear peptide before conjugation has the sequence:

[Ac]ACPQDLELCTFLFGDCA

conjugation to 1,3, 5-tris (bromomethyl) benzene (TBMB, Sigma) was performed as follows. By H₂O Linear peptide was diluted to about 35mL, added about 500. mu.L of 100mM TBMB in acetonitrile and incubated with 5mL of 1M NH₄HCO₃The aqueous solution initiates the reaction. The reaction was allowed to proceed at room temperature for about 30 to 60 minutes and lyophilized once the reaction was complete (as judged by MALDI). After lyophilization, the modified peptide was purified using a Gemini C18 column (Phenomenex) and the acid was changed to 0.1% trifluoroacetic acid. Pure fractions containing the correct TMB modifying substance were pooled, lyophilized and stored at-20 ℃.

The resulting bicyclic derivative designated BCY00008655 shows high affinity for IL-17A. The measured affinity (Ki) of the derivative for IL-17A was 93 nM.

Examples 1 to 7

Bicyclic peptide ligands according to the invention were prepared corresponding to the bicyclic region of the peptide ligand of reference example 1, wherein one, two or three cysteine residues were substituted by N-mepap residues, wherein the N-mepap residues form alkylamino bonds with the TBMB scaffold. The structures of these derivatives are schematically shown in fig. 2 to 8.

The cyclization reaction with TBMB was carried out in an acetonitrile/water mixture in the presence of DIPEA as a base for 1 to 16 hours as described in more detail in PCT/EP2017/083953 and PCT/EP2017/083954 filed on 12, 20, 2017. In contrast to the cyclization of reference example 1, when conventional NaHCO was used₃The yield is relatively low as a base.

The measured Ki values are shown in table 1. It can be seen that all examples show high binding affinity for IL-17A, indicating that the change to an alkylamino bond in this example results in relatively small binding affinity changes relative to the thioether-linked derivative in reference example 1.

Table 1: IL-17 binding dap (Me) -substituted bicyclics

Reference examples A1-A6:

as described in detail in our prior application GB1720932.1 filed on 12/15/2017, the following reference peptide ligands with TBMB scaffolds bonded with three thioether linkages to cysteine residues of the specified peptide sequence were prepared and evaluated for affinity for IL-17.

Table 1: reference examples A1-A6

And nt is not measured.

In view of the above results obtained in examples 1-7, it is expected that the derivatives of reference examples A1-A6 according to the present invention (i.e., having alkylamino linkages instead of one, two or three of the thioether linkages in the reference examples) will also exhibit affinity for IL-17. Accordingly, all such derivatives having affinity for IL-17 are included within the scope of the present invention.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and alterations of the described aspects and embodiments of the invention will be apparent to those skilled in the art without departing from the scope of the invention. While the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.